首页 | 本学科首页   官方微博 | 高级检索  
检索        

阿替普酶不同剂量治疗急性缺血性脑卒中的疗效比较
作者姓名:曲珊珊
作者单位:淄博矿业集团有限责任公司中心医院药剂科
摘    要:目的 比较阿替普酶不同剂量治疗急性缺血性脑卒中的疗效.方法 对我院收治的100例缺血性脑卒中患者进行研究,患者就诊时间为2018年10月—2020年10月,根据患者就诊顺序进行分组,每组各50例.对照组采用阿替普酶0.6 mg/kg静脉溶栓治疗,研究组采用阿替普酶0.9 mg/kg静脉溶栓治疗.比较两组患者治疗前与治疗...

关 键 词:缺血性脑卒中  阿替普酶  静脉溶栓  NIHSS评分  mRS评分  炎症因子

Comparison of Therapeutic Effects of Different Doses of Alteplase in the Treatment of Acute Ischemic Stroke
Authors:QU Shanshan
Institution:(Department of Pharmacy,Central Hospital of ZiboMining Group Co.,Ltd.,Zibo Shandong 255120,China)
Abstract:Objective To compare the efficacy of alteplase at different doses in the treatment of acute ischemic stroke.Methods A total of 100 patients with ischemic stroke admitted to our hospital were studied.The time of visit was from October 2018 to October 2020.The patients were grouped according to the order of visit,50 patients in each group.The control group was treated with intravenous thrombolysis with 0.6mg/kg aputease,while the study group was treated with intravenous thrombolysis with 0.9mg/kg aputease.NIHSS score,mRS score,inflammatory factor level,total effective rate of treatment,and incidence of adverse reactions were compared between the two groups before and after treatment.Results There was no significant difference in NIHSS score and mRS score between the two groups before and after treatment(P>0.05).After 3 months of treatment,the reexamination showed that the NIHSS and mRS scores of the study group were significantly lower than those of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the level of CRP,IL-6 and TNF-αbefore treatment between the two groups(P>0.05).After treatment,the levels of CRP,IL-6 and TNF-αin the study group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total effective rate and incidence of adverse events between the two groups(P>0.05).Conclusion The short-term efficacy and safety of low dose and standard dose of aptease in the treatment of ischemic stroke are comparable,but the standard dose is more effective in reducing inflammation and improving the prognosis of patients with ischemic stroke.
Keywords:ischemic stroke  aptease  intravenous thrombolysis  NIHSS score  mRS score  inflammatory factor
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号